Antibiotics Partnering Terms and Agreements, New Report Launched

The Antibiotics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibiotic partnering deals and agreements entered into by the worlds leading healthcare companies.

Description

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

• Trends in antibiotics partnering deals
• Disclosed headlines, upfronts, milestones and royalties by stage of development
• Antibiotics partnering contract documents
• Top antibiotics deals by value

The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

• Antibiotics
• Aminoglycosides
• Cephalosporin
• Clindamycin
• Macrolides
• Penicillin
• Quinolones
• Sulfonamides
• Tetracycline

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 150 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What are the precise rights granted or optioned?
• What is the payment structure for the deal?
• How aresalesand payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announced along with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009 organized by antibiotics technology focus. The chapter includes deals listed by antibiotics and broken down into individual type of antibiotics- aminoglycosides, cephalosporin, clindamycin, macrolides, metronidazole, penicillin, quinolones and tetracycline. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z , stage of development, deal type and therapy focus, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

Antibiotics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Antibiotics Partnering Terms and Agreements includes:

• Trends in antibiotics dealmaking in the biopharma industry since 2009
• Analysis of antibiotics deal structure
• Access to headline, upfront, milestone and royalty data
• Case studies of real-life antibiotics deals
• Access to over 150 antibiotics deal records and contract documents where available
• The leading antibody deals by value since 2009
• Most active antibiotics dealmakers since 2009
• The leading antibiotics partnering resources

In Antibiotics Partnering Terms and Agreements, the available contracts are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Antibiotics Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of antibiotics deal trends since 2009
• Access to headline, upfront, milestone and royalty data
• Analysis of the structure of antibiotics agreements with numerous real life case studies
• Comprehensive access to over 150 antibiotics deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
• Full listing of antibiotics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
• Identify leading antibiotics deals by value since 2009
• Identify the most active antibiotics dealmakers since 2009
• Detailed access to actual antibiotics contracts enter into by the leading fifty big pharma and big biotech companies
• Insight into the terms included in a antibiotics agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Spanning over 499 pages, “Antibiotics Partnering Terms and Agreements” report covering the Executive Summary, Introduction, Trends in antibiotics dealmaking, Big pharma antibiotics deals, Big biotech antibiotics deals, Antibiotics partnering contracts directory, Antibiotics dealmaking by technology type. The report covered few companies are - Ab Sciex,Abbott Laboratories,Accelr8,Acella Pharmaceuticals,Achaogen,Actavis,Advance Trading,Advanced Life Sciences,Advanced Technology Company,Affibody,Akorn,Albert Einstein College of Medicine,Alfa Wassermann,ALK-Abello,AllerQuest,Almac Pharma Services,AmpliPhi Biosciences,Anacor Pharmaceuticals,Angelini Pharma

For more information see – http://mrr.cm/ZMj

Find all Healthcare Reports at: http://www.marketresearchreports.com/healthcare